OK HB2251

Expands Oklahoma's cannabidiol (CBD) clinical trial program beyond patients 18 and younger with severe epilepsy to include persons of any age with "serious medical conditions" not adequately treated by traditional therapies

Defines "serious medical condition" to include AIDS, cancer, chronic pain, glaucoma, PTSD, seizures, multiple sclerosis-related muscle spasms, bipolar disorder, ADHD, and conditions that substantially limit major life activities

Authorizes physicians licensed in Oklahoma to serve as principal investigators for FDA-approved clinical trials using cannabidiol for both severe epilepsy and serious medical conditions

Requires cannabidiol to have THC concentration of no more than 0.3% and be delivered in liquid form, with manufacturing and testing in FDA-approved facilities

Effective date of November 1, 2016